Phosphorylation of Estrogen Receptor aSerine 167 is Predictive of Response to Endocrine Therapy and Increases Post Relapse Survival in Metastatic Breast Cancer
9th Sep 2005, 23:58 GMT
Data suggest that phosphorylation of ER- aSer167 is helpful in selecting patients who may benefit from endocrine therapy and is a prognostic marker in metastatic breast cancer. Breast Cancer Research
Latest news from Medscape Headlines:
- New Treatment for Ischemic Stroke on the Horizon
- Adding Bevacizumab to First-Line Lung Cancer Therapy Shows Potential
- Type 1 and 2 T Helper Cell-mediated Colitis
- Radiation Therapy for Chronic Vesicular Hand Dermatitis
- November 14, 2006: In the News
- Alcoholic Liver Disease-Pathophysiological Aspects and Risk Factors
- Overweight in Celiac Disease: Prevalence, Clinical Characteristics, and Effect of a Gluten-Free Diet
- Bleeding-Edge Benefits
- End-Stage Renal Disease and Drug-Eluting Stents: One Small Step Forward?
- November 13, 2006: In the News